Literature DB >> 35932909

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.

Terry W Moody1, Irene Ramos-Alvarez2, Robert T Jensen2.   

Abstract

Neurotensin (NTS) receptor 1 regulates the growth non-small cell lung cancer (NSCLC) cells. NTS binds with high affinity to NTSR1, leading to increased tyrosine phosphorylation of the EGFR and HER2. Using Calu3, NCI-H358, or NCI-H441 cells, the effects of NTS on HER3 transactivation were investigated. HER3 tyrosine phosphorylation was increased by NTS or neuregulin (NRG1) addition to NSCLC cells. NCI-H358, NCI-H441, and Calu-3 cells have HER3, NTSR1 and neuregulin (NRG)1 protein. NTSR1 regulation of HER3 transactivation was impaired by SR48692 (NTSR1 antagonist) or monoclonal antibody (mAb)3481 (HER3 blocker). Immunoprecipitation experiments indicated that NTS addition to NCI-H441cells resulted in the formation of EGFR/HER3 and HER2/HER3 heterodimers. The ability of NTS to increase HER3 tyrosine phosphorylation was impaired by GM6001 (MMP inhibitor), PP2 (Src inhibitor), Tiron (superoxide scavenger), or N-acetylcysteine (antioxidant). Adding NTS to NSCLC cells increased phosphorylation of ERK, HER3, and AKT. NTS or NRG1 increased colony formation of NSCLC cells which was strongly inhibited by SR48692 and mAb3481. The results indicate that NTSR1 regulates HER3 transactivation in NSCLC cells leading to increased proliferation. Published by Elsevier Inc.

Entities:  

Keywords:  HER3; Lung cancer; Neuregulin 1; Neurotensin; Phosphorylation; Signal transduction

Mesh:

Substances:

Year:  2022        PMID: 35932909      PMCID: PMC9529830          DOI: 10.1016/j.peptides.2022.170858

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.867


  44 in total

1.  Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas.

Authors:  Frédérique Souazé; Véronique Viardot-Foucault; Nicolas Roullet; Mireille Toy-Miou-Leong; Anne Gompel; Erik Bruyneel; Eva Comperat; Maree C Faux; Marc Mareel; William Rostène; Jean-François Fléjou; Christian Gespach; Patricia Forgez
Journal:  Carcinogenesis       Date:  2005-11-19       Impact factor: 4.944

2.  Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer.

Authors:  M Ocejo-Garcia; S I Ahmed; J M Coulson; P J Woll
Journal:  Lung Cancer       Date:  2001-07       Impact factor: 5.705

Review 3.  Functional domains of the subtype 1 neurotensin receptor (NTS1).

Authors:  Patrick Kitabgi
Journal:  Peptides       Date:  2006-08-09       Impact factor: 3.750

4.  Neurotensin elevates cytosolic calcium in small cell lung cancer cells.

Authors:  J Staley; G Fiskum; T P Davis; T W Moody
Journal:  Peptides       Date:  1989 Nov-Dec       Impact factor: 3.750

5.  Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma.

Authors:  S M Wood; J R Wood; M A Ghatei; Y C Lee; D O'Shaughnessy; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

6.  Neurotensin binds with high affinity to small cell lung cancer cells.

Authors:  A E Allen; D N Carney; T W Moody
Journal:  Peptides       Date:  1988       Impact factor: 3.750

Review 7.  The EGFR family: not so prototypical receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger; Kathryn M Ferguson
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-04-01       Impact factor: 10.005

8.  Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Eur J Pharmacol       Date:  2019-10-12       Impact factor: 4.432

9.  Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.

Authors:  Mohamad Younes; Zherui Wu; Sandra Dupouy; Audrey Mansuet Lupo; Najat Mourra; Takashi Takahashi; Jean François Fléjou; Jean Trédaniel; Jean François Régnard; Diane Damotte; Marco Alifano; Patricia Forgez
Journal:  Oncotarget       Date:  2014-09-30

Review 10.  Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.